Academic Promotion and Oncology Drug Development: Role, Responsibilities, and Integrity [0.03%]
学术晋升与肿瘤药物研发：作用、责任和诚信
Nora Janjan
Nora Janjan
Nora Janjan, MD, MPSA, MBA, gives her perspective on oncology drug development through academic promotion.
Perspectives on Follicular Lymphoma Treatment From New and Experienced Clinicians: New, Old, & Old Is New [0.03%]
从新晋和经验丰富的临床医生角度看 follicular lymphoma 的治疗：新、旧与旧即是新
Jonathan R Day,Brian K Link
Jonathan R Day
Jonathan R. Day, MD, PharmD, and Brian K. Link, MD, give their perspective on emerging treatments for follicular lymphoma.
Michael A Spinner,Ranjana H Advani
Michael A Spinner
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is an aggressive and biologically heterogeneous disease. Risk stratification and treatment algorithms vary based on stage of disease and bulk along with...
Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017 [0.03%]
2006年至2017年老年膀胱侵袭性肌层膀胱癌新辅助化疗应用的流行病学研究
Natasza Posielski,Hannah Koenig,On Ho et al.
Natasza Posielski et al.
Objectives/Introduction Neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) is associated with survival benefit across patients of all ages, yet it is not offered to many elderly patient...
Cisplatin Neoadjuvant Chemotherapy in an Aging Population With Muscle-Invasive Bladder Cancer [0.03%]
老年肌层浸润性膀胱癌患者接受顺铂新辅助化疗
Jun Gong
Jun Gong
Jun Gong, MD, gives his perspective on neoadjuvant chemotherapy in elderly patients with muscle-invasive bladder cancer.
Female Representation in Clinical Practice Guideline Panels in 2 Major Cancer Organizations [0.03%]
两大癌症组织临床实践指南委员会的女性代表情况
Madhuri Chengappa,Ronald S Go,Ariela Marshall et al.
Madhuri Chengappa et al.
Over the last decade, the proportion of female panelists in NCCN CPGPs has doubled, with more than 50% of members of 60 CPGPs in 2020 being women. In ESMO, although there was an increase in female representation in a few CPGPs from 2010 to ...
Mehmet Copur
Mehmet Copur
Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma [0.03%]
胰腺癌血液分子标志物的鉴定
Christine Chung,Rachael Galvin,Ella Achenbach et al.
Christine Chung et al.
Background: Molecular profiling is being explored in pancreatic adenocarcinoma (PDAC) as a tool to assist with early detection, prognosis, and patient selection in targeted therapy clinical trials. Due to the challenges and risks of traditi...
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab [0.03%]
利妥昔单抗皮下注射的临床应用及实践效率评估研究
Esther Drill,Annie Qiu,Sheila Shapouri et al.
Esther Drill et al.
INTRODUCTION: A subcutaneous (SC) formulation of the anti-CD20 monoclonal antibody, rituximab (Rituxan), is approved in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). Rituximab-SC (R...
Sunil Reddy
Sunil Reddy